# Omega Fund Management, LLC: Form 13F holdings

An institutional investment manager in Boston, MA. SEC CIK 1637359.

- Quarter ended: 2026-06-30
- Filed: 2026-08-14
- Reported value: $185.7m
- Positions: 10 (10 lines in the filing's table; lines for the same security and option type are added together here)
- Compared with: the 13F for the quarter ended 2026-03-31
- Filing: https://www.sec.gov/Archives/edgar/data/1637359/000119312526350681/

## Holdings

As filed, largest first. Reported value is what the manager stated at the quarter end (Jun 30, 2026), in US dollars; it is filing data, not a price. Weight is the share of the total reported value.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| [Bicara Therapeutics Inc. (BCAX)](/companies/bcax.md) | Common Stock | $54.1m | 29.1% | 1,822,150 |  | Reduced −570,000 |
| [Nuvation Bio Inc. (NUVB)](/companies/nuvb.md) | Common Stock Class A | $45.9m | 24.7% | 8,081,089 |  | Unchanged |
| Kestra Med Technologies Ltd | Common Stock | $26.0m | 14.0% | 1,022,149 |  | Unchanged |
| [BridgeBio Oncology Therapeutics Inc. (BBOT)](/companies/bbot.md) | Common Stock | $25.1m | 13.5% | 3,289,661 |  | Unchanged |
| [Beta Bionics Inc. (BBNX)](/companies/bbnx.md) | Common Stock | $20.6m | 11.1% | 1,316,183 |  | Unchanged |
| [Alumis Inc. (ALMS)](/companies/alms.md) | Common Stock | $6.8m | 3.7% | 241,255 |  | Unchanged |
| [Sana Biotechnology, Inc. (SANA)](/companies/sana.md) | Common Stock | $2.9m | 1.6% | 843,750 |  | Unchanged |
| [ImageneBio, Inc. (IMA)](/companies/ima.md) | Common Stock | $2.7m | 1.4% | 455,361 |  | Unchanged |
| enGene Holdings Inc. | Common Stock | $1.5m | 0.8% | 876,357 |  | Unchanged |
| [Odyssey Therapeutics Inc. (ODTX)](/companies/odtx.md) | Common Stock | $54.1k | <0.1% | 2,893 |  | New +2,893 |

## Sold out

Held at the end of the quarter before and not reported this quarter.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| [Replimune Group (REPL)](/companies/repl.md) | Common Stock | $0 | 0.0% | 0 |  | Sold out −248,672 |

Source: SEC EDGAR, Form 13F-HR, accession 0001193125-26-350681. Last ingested by Listed: Oct 22, 2026, 05:26 ET. No prices; not investment advice.